2018: Entos Pharmaceuticals (Entos) and Oisin Biotechnologies (Oisin) launched OncoSenX, a late-stage pre-clinical cancer therapy company. The cancer therapy approach under development by OncoSenX is a less invasive, more precise, well-tolerated and highly adaptable intervention of this complex and devastating disease.
This joint venture will commercialize an oncology suicide gene therapy treatment that targets transcriptional activity of solid tumors. The treatment comprises two novel components: Entos’ untargeted lipid nanoparticle Fusogenix platform as the delivery method and Oisin’s highly targeted plasmid DNA as the therapeutic payload. The DNA payload system implements logic gates, IF/OR/AND, allowing precise targeting of cell populations based on their genetic activity and leaving adjacent cells unharmed. Therefore, together, this loaded nanoparticle induces apoptosis in cancerous cells, leading to their destruction, without harming adjacent cells.
OncoSenX partners with Oisin Biotechnologies, Entos Pharmaceuticals, The Methuselah Fund, The Methuselah Foundation, The SENS Research Foundation and the laboratory of Dr. John Lewis at University of Alberta, Canada.
John Lewis is co-founder of OncoSenX along with Matthew Scholz.
Oisín Biotechnologies is a senescence-focused biotechnology company. Their ground-breaking research and technology demonstrate that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. Matthew Scholz is the CEO of Oisin and the Chairman and CEO of OncoSenX. Stephen Hilbert is the President of Corporate Development for both Oisin and OncoSenX. Eric Garcia serves as the COO for both Oisin and OncoSenX.
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.